GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anika Therapeutics Inc (FRA:AKP) » Definitions » Cyclically Adjusted FCF per Share

Anika Therapeutics (FRA:AKP) Cyclically Adjusted FCF per Share : €1.30 (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Anika Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Anika Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2024 was €-0.280. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €1.30 for the trailing ten years ended in Jun. 2024.

During the past 12 months, Anika Therapeutics's average Cyclically Adjusted FCF Growth Rate was -13.80% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -2.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 2.70% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 17.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Anika Therapeutics was 88.20% per year. The lowest was -18.30% per year. And the median was 29.20% per year.

As of today (2024-09-21), Anika Therapeutics's current stock price is €22.60. Anika Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 was €1.30. Anika Therapeutics's Cyclically Adjusted Price-to-FCF of today is 17.38.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Anika Therapeutics was 114.00. The lowest was 10.89. And the median was 27.31.


Anika Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Anika Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics Cyclically Adjusted FCF per Share Chart

Anika Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.46 1.28 1.56 1.60 1.37

Anika Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.47 1.51 1.37 1.32 1.30

Competitive Comparison of Anika Therapeutics's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Anika Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Anika Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.28/132.5538*132.5538
=-0.280

Current CPI (Jun. 2024) = 132.5538.

Anika Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 0.359 100.428 0.474
201412 0.772 99.070 1.033
201503 0.225 99.621 0.299
201506 0.582 100.684 0.766
201509 0.466 100.392 0.615
201512 0.534 99.792 0.709
201603 0.095 100.470 0.125
201606 -0.261 101.688 -0.340
201609 0.507 101.861 0.660
201612 0.295 101.863 0.384
201703 0.857 102.862 1.104
201706 0.238 103.349 0.305
201709 0.528 104.136 0.672
201712 0.253 104.011 0.322
201803 0.389 105.290 0.490
201806 0.214 106.317 0.267
201809 0.574 106.507 0.714
201812 0.606 105.998 0.758
201903 0.459 107.251 0.567
201906 0.274 108.070 0.336
201909 0.607 108.329 0.743
201912 0.781 108.420 0.955
202003 0.020 108.902 0.024
202006 0.212 108.767 0.258
202009 0.334 109.815 0.403
202012 0.123 109.897 0.148
202103 -0.166 111.754 -0.197
202106 0.112 114.631 0.130
202109 0.045 115.734 0.052
202112 0.200 117.630 0.225
202203 -0.201 121.301 -0.220
202206 0.075 125.017 0.080
202209 0.070 125.227 0.074
202212 -0.132 125.222 -0.140
202303 -0.319 127.348 -0.332
202306 -0.613 128.729 -0.631
202309 0.368 129.860 0.376
202312 0.113 129.419 0.116
202403 -0.121 131.776 -0.122
202406 -0.280 132.554 -0.280

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Anika Therapeutics  (FRA:AKP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Anika Therapeutics's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=22.60/1.3
=17.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Anika Therapeutics was 114.00. The lowest was 10.89. And the median was 27.31.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Anika Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Anika Therapeutics Business Description

Traded in Other Exchanges
Address
32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.